• Idorsia named Roland Wandeler as CEO, effective Oct. 1, 2026.
• Wandeler is President, Biopharma at Grifols; previously held senior roles at Amgen, served as MorphoSys COO; holds an ETH Zurich PhD.
• Jean-Paul Clozel will remain CEO until Oct. 1, 2026; continues as board chairman thereafter.
• Benjamin Limal, President Europe and International Markets, joins the executive committee.
• Dominique Le Terrier becomes Head of Global Commercial Strategy and New Product Planning; Begoña Carreño-Gómez named Chief Business Development Officer from Nov. 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010100OMX_____CNEWS_EN_GNW1001210523_en) on July 01, 2026, and is solely responsible for the information contained therein.